{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:36:38Z","timestamp":1793406998590,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI143951"],"award-info":[{"award-number":["R01 AI143951"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bmc.2023.117295","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T12:13:42Z","timestamp":1682684022000},"page":"117295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633"],"prefix":"10.1016","volume":"86","author":[{"given":"Edmund","family":"Oboh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanner J.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5483-8063","authenticated-orcid":false,"given":"Adriana S.","family":"Maribona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brylon N.","family":"Denman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Huston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-619X","authenticated-orcid":false,"given":"Marvin J.","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2023.117295_b0005","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(12)60560-1","article-title":"with time trends since 2000","volume":"379","author":"Liu","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2023.117295_b0010","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(16)31529-X","article-title":"Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study","volume":"388","author":"Liu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2023.117295_b0015","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00042560-199902010-00007","article-title":"Declining CD4+ T-lymphocyte counts are associated with increased risk of enteric parasitosis and chronic diarrhea: results of a 3-year longitudinal study","volume":"20","author":"Navin","year":"1999","journal-title":"Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology"},{"key":"10.1016\/j.bmc.2023.117295_b0020","doi-asserted-by":"crossref","first-page":"e0004729","DOI":"10.1371\/journal.pntd.0004729","article-title":"The Burden of Cryptosporidium Diarrheal Disease among Children < 24 Months of Age in Moderate\/High Mortality Regions of Sub-Saharan Africa and South Asia, Utilizing Data from the Global Enteric Multicenter Study (GEMS)","volume":"10","author":"Sow","year":"2016","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"10.1016\/j.bmc.2023.117295_b0025","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199407213310304","article-title":"A massive outbreak in Milwaukee of cryptosporidium infection transmitted through the public water supply","volume":"331","author":"Mac","year":"1994","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.bmc.2023.117295_b0030","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.01505-17","article-title":"A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box","volume":"62","author":"Jumani","year":"2018","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.bmc.2023.117295_b0035","first-page":"CD004932","article-title":"Prevention and treatment of cryptosporidiosis in immunocompromised patients","author":"Abubakar","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.bmc.2023.117295_b0040","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0140-6736(02)11401-2","article-title":"Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial","volume":"360","author":"Amadi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2023.117295_b0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/cid\/ciaa421","article-title":"Clofazimine for treatment of cryptosporidiosis in human immunodeficiency virus infected adults: an experimental medicine, randomized, double-blind, placebo-controlled phase 2a trial","volume":"73","author":"Tam","year":"2021","journal-title":"Clin. Infect. Dis"},{"key":"10.1016\/j.bmc.2023.117295_b0050","doi-asserted-by":"crossref","first-page":"11729","DOI":"10.1021\/acs.jmedchem.1c01136","article-title":"Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin","volume":"64","author":"Oboh","year":"2021","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2023.117295_b0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/infdis\/jiz105","article-title":"Piperazine-derivative MMV665917: an effective drug in the diarrheic piglet model of Cryptosporidium hominis","volume":"220","author":"Lee","year":"2019","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.bmc.2023.117295_b0060","doi-asserted-by":"crossref","first-page":"e0006183","DOI":"10.1371\/journal.pntd.0006183","article-title":"Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model","volume":"12","author":"Stebbins","year":"2018","journal-title":"PLoS Neglected Tropical Diseases"},{"key":"10.1016\/j.bmc.2023.117295_b0065","doi-asserted-by":"crossref","unstructured":"W.C. Van Voorhis, J.H. Adams, R. Adelfio, V. Ahyong, M.H. Akabas, P. Alano, A. Alday, Y. Aleman Resto, A. Alsibaee, A. Alzualde, K.T. Andrews, S.V. Avery, V.M. Avery, L. Ayong, M. Baker, S. Baker, C. Ben Mamoun, S. Bhatia, Q. Bickle, L. Bounaadja, T. Bowling, J. Bosch, L.E. Boucher, F.F. Boyom, J. Brea, M. Brennan, A. Burton, C.R. Caffrey, G. Camarda, M. Carrasquilla, D. Carter, M.B. Cassera, K.C.-C. Cheng, W. Chindaudomsate, A. Chubb, B.L. Colon, D.D. Colon-Lopez, Y. Corbett, G.J. Crowther, N. Cowan, S. D'Alessandro, N.L. Dang, M. Delves, J.L. De Risi, A.Y. Du, S. Duffy, S.A.E.-S. El-Sayed, M.T. Ferdig, J.A. Fernandez Robledo, D.A. Fidock, I. Florent, P.V.T. Fokou, A. Galstian, F.J. Gamo, S. Gokool, B. Gold, T. Golub, G.M. Goldgof, R. Guha, W.A. Guiguemde, N. Gural, R.K. Guy, M.A.E. Hansen, K.K. Hanson, A. Hemphill, R. Hooft van Huijsduijnen, T. Horii, P. Horrocks, T.B. Hughes, C. Huston, I. Igarashi, K. Ingram-Sieber, M.A. Itoe, A. Jadhav, A.N. Jensen, L.T. Jensen, R.H.Y. Jiang, A. Kaiser, J. Keiser, T. Ketas, S. Kicka, S. Kim, K. Kirk, V.P. Kumar, D.E. Kyle, M.J. Lafuente, S. Landfear, N. Lee, S. Lee, A.M. Lehane, F. Li, D. Little, L. Liu, M. Llinas, M.I. Loza, A. Lubar, L. Lucantoni, I. Lucet, L. Maes, D. Mancama, N.R. Mansour, S. March, S. McGowan, I.M. Vera, S. Meister, L. Mercer, J. Mestres, A.N. Mfopa, R.N. Misra, S. Moon, J.P. Moore, F. Morais Rodrigues da Costa, J. Muller, A. Muriana, S.N. Hewitt, B. Nare, C. Nathan, N. Narraidoo, S. Nawaratna, K.K. Ojo, D. Ortiz, G. Panic, G. Papadatos, S. Parapini, K. Patra, N. Pham, S. Prats, D.M. Plouffe, S.-A. Poulsen, A. Pradhan, C. Quevedo, R.J. Quinn, C.A. Rice, M.A. Rizk, A. Ruecker, R. St. Onge, R.S. Ferreira, J. Samra, N.G. Robinett, U. Schlecht, M. Schmitt, F.S. Villela, F. Silvestrini, R. Sinden, D.A. Smith, T. Soldati, A. Spitzmuller, S.M. Stamm, D.J. Sullivan, W. Sullivan, S. Suresh, B.M. Suzuki, Y. Suzuki, S.J. Swamidass, D. Taramelli, L.R.Y. Tchokouaha, A. Theron, D. Thomas, K.F. Tonissen, S. Townson, A.K. Tripathi, V. Trofimov, K.O. Udenze, I. Ullah, C. Vallieres, E. Vigil, J.M. Vinetz, P.V. Vinh, H. Vu, N.-a. Watanabe, K. Weatherby, P.M. White, A.F. Wilks, E.A. Winzeler, E. Wojcik, M. Wree, W. Wu, N. Yokoyama, P.H.A. Zollo, N. Abla, B. Blasco, J. Burrows, B. Laleu, D. Leroy, T. Spangenberg, T. Wells, P.A. Willis, Open source drug discovery with the malaria box compound collection for neglected diseases and beyond, PLoS Pathog., 2016;12:e1005763\/1005761-e1005763\/1005723.","DOI":"10.1371\/journal.ppat.1005763"},{"key":"10.1016\/j.bmc.2023.117295_b0070","doi-asserted-by":"crossref","first-page":"e3001604","DOI":"10.1371\/journal.pbio.3001604","article-title":"Live imaging of the Cryptosporidium parvum life cycle reveals direct development of male and female gametes from type I meronts","volume":"20","author":"English","year":"2022","journal-title":"PLoS Biology"},{"key":"10.1016\/j.bmc.2023.117295_b0075","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1038\/s41467-019-09880-w","article-title":"A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors","volume":"10","author":"Jumani","year":"2019","journal-title":"Nature Communications"},{"key":"10.1016\/j.bmc.2023.117295_b0080","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00052-20","article-title":"Defining Stage-Specific Activity of Potent New Inhibitors of Cryptosporidium parvum Growth In Vitro","volume":"11","author":"Funkhouser-Jones","year":"2020","journal-title":"MBio"},{"key":"10.1016\/j.bmc.2023.117295_b0085","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1021\/jm060379l","article-title":"Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups","volume":"49","author":"Jamieson","year":"2006","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2023.117295_b0090","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/AAC.02460-12","article-title":"Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth","volume":"57","author":"Bessoff","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.bmc.2023.117295_b0095","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1016\/j.bmcl.2009.05.062","article-title":"Rapid assessment of a novel series of selective CB2 agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis","volume":"19","author":"Ryckmans","year":"2009","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.bmc.2023.117295_b0100","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.bmc.2023.117295_b0105","first-page":"381","article-title":"Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks","volume":"45","author":"Edwards","year":"2010","journal-title":"Ann. Rep. Med. Chem."},{"key":"10.1016\/j.bmc.2023.117295_b0110","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1021\/acs.jcim.7b00315","article-title":"Developing Collaborative QSAR Models Without Sharing Structures","volume":"57","author":"Gedeck","year":"2017","journal-title":"Journal of Chemical Information and Modeling"},{"key":"10.1016\/j.bmc.2023.117295_b0115","unstructured":"C. Weatherall, https:\/\/support.collaborativedrug.com\/hc\/en-us\/articles\/11718851408660-Log-P-Calculated-by-CDD-Vault-During-Chemical-Registration, accessed May 1, 2023."},{"key":"10.1016\/j.bmc.2023.117295_b0120","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1021\/acs.jcim.9b00498","article-title":"Prediction of pKa Using Machine Learning Methods with Rooted Topological Torsion Fingerprints: Application to Aliphatic Amines","volume":"59","author":"Lu","year":"2019","journal-title":"Journal of Chemical Information and Modeling"},{"key":"10.1016\/j.bmc.2023.117295_b0125","unstructured":"C. Weatherall, https:\/\/support.collaborativedrug.com\/hc\/en-us\/articles\/11656609142292-pKa-Calculated-by-CDD-Vault-During-Chemical-Registration, accessed May 1, 2023."},{"key":"10.1016\/j.bmc.2023.117295_b0130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijpara.2020.01.006","article-title":"Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned","volume":"50","author":"Choi","year":"2020","journal-title":"International Journal for Parasitology"},{"key":"10.1016\/j.bmc.2023.117295_b0135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1517\/14728222.10.2.319","article-title":"QPatch: the past, present and future of automated patch clamp","volume":"10","author":"Mathes","year":"2006","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"10.1016\/j.bmc.2023.117295_b0140","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1021\/acs.orglett.6b02591","article-title":"Pd-Catalyzed Synthesis of Piperazine Scaffolds Under Aerobic and Solvent-Free Conditions","volume":"18","author":"Reilly","year":"2016","journal-title":"Organic Letters"},{"key":"10.1016\/j.bmc.2023.117295_b0145","first-page":"5","article-title":"Design and facile synthesis of 6-(benzothiophen-3-yl)-3-para-substituted-[1,2,4] triazolo [3,4-a] phthalazine derivatives as anti-microbial agents","volume":"6","author":"Prabhakar","year":"2016","journal-title":"Res. J. Chem. Sci."},{"key":"10.1016\/j.bmc.2023.117295_b0150","unstructured":"Bradbury R.H., Carr G.R., Rabow A.A., Rao Korupoju S., Tumma H. Preparation of triazolopyridazine derivatives for use in the treatment of prostate cancer, WO2010092371A1, August 19, 2010."},{"key":"10.1016\/j.bmc.2023.117295_b0155","unstructured":"Sun C., Huang Y., Sitkoff D.F., Lee T., Ewing W. Preparation of bicyclic heterocycles as cannabinoid receptor 1 modulators.US20060287324A1, December 21, 2006."},{"key":"10.1016\/j.bmc.2023.117295_b0160","first-page":"1118","article-title":"Design, synthesis and biological activity of novel (3-substituted phenyl-2-propen-1-ylidene)-benzoylhydrazones","volume":"34","author":"Xu","year":"2014","journal-title":"Youji Huaxue"},{"key":"10.1016\/j.bmc.2023.117295_b0165","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1016\/0040-4039(96)01351-2","article-title":"An efficient general method for esterification of aromatic carboxylic acids","volume":"37","author":"Hosangadi","year":"1996","journal-title":"Tetrahedron Letters"},{"key":"10.1016\/j.bmc.2023.117295_b0170","unstructured":"Jefferson E.A., Seth P., Robinson D.E. Jr., Migawa M.T., Griffey R.H., Swayze E.E. Preparation of guanidinoazines as antivirals.WO2004037166A2, May 06, 2004."},{"key":"10.1016\/j.bmc.2023.117295_b0175","unstructured":"Molette J., Gabellieri E., Darmency V. Preparation of bicyclic compounds for diagnosis and therapy. WO2017153601A1, September 14, 2017."},{"key":"10.1016\/j.bmc.2023.117295_b0180","doi-asserted-by":"crossref","first-page":"15825","DOI":"10.1021\/acs.joc.1c02023","article-title":"KOtBu-Promoted Halogen-Bond-Assisted Intramolecular C-S Cross-Coupling of o-Iodothioanilides for the Synthesis of 2-Substituted Benzothiazoles","volume":"86","author":"Nandy","year":"2021","journal-title":"The Journal of Organic Chemistry"},{"key":"10.1016\/j.bmc.2023.117295_b0185","doi-asserted-by":"crossref","first-page":"12564","DOI":"10.1021\/acs.chemrev.6b00512","article-title":"Applications of Palladium-Catalyzed C-N Cross-Coupling Reactions","volume":"116","author":"Ruiz-Castillo","year":"2016","journal-title":"Chemical Reviews"},{"key":"10.1016\/j.bmc.2023.117295_b0190","unstructured":"Vechorkin O., Qi C., Nguyen M., Wang A., Yao W. Preparation of bicyclic heterocycles as FGFR inhibitors. WO2021007269A1, April 01, 2021."},{"key":"10.1016\/j.bmc.2023.117295_b0195","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1007\/s11164-020-04260-2","article-title":"Naturally occurring organic acids for organocatalytic synthesis of pyrroles via Paal-Knorr reaction","volume":"46","author":"Mohsenzadeh","year":"2020","journal-title":"Research on Chemical Intermediates"},{"key":"10.1016\/j.bmc.2023.117295_b0200","unstructured":"Bourotte M., Delhomel J.-F., Dubernet M., Gouy M.-H. Preparation of derivs. of 6-substituted triazolopyridazines as Rev-Erb agonists for treating inflammatory, circadian rhythm-related, or cardiometabolic disorders. WO2013045519A1, April 04, 2013."},{"key":"10.1016\/j.bmc.2023.117295_b0205","volume":"25","author":"Lindsley","year":"2021","journal-title":"Heterocyclic compounds as competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor M5 and their preparation.WO2021237038A1"},{"key":"10.1016\/j.bmc.2023.117295_b0210","unstructured":"Galemmo R.A., West A.B., Maddry J.A., Ananthan S., Pathak A.K., Valiyaveettil J. Preparation of triazolopyridazine compounds for use as inhibitors of LRRK2 kinase for treatment of neurodegenerative and other diseases. WO2013166276A1, November 07, 2013."},{"key":"10.1016\/j.bmc.2023.117295_b0215","first-page":"643","article-title":"Design and facile synthesis of 6-(thiophen-3-yl)-3-para-substituted-[1,2,4]triazolo[3,4-a]phthalazine derivatives as anti-microbial agents","volume":"6","author":"Prabhakar","year":"2016","journal-title":"Heterocycl. Lett."},{"key":"10.1016\/j.bmc.2023.117295_b0220","unstructured":"Kawano Y., Miyake A., Ashida Y. Triazolopyridazines process and intermediates for their preparation and their use as medicaments. WO9608496A1, March 21,1996."},{"key":"10.1016\/j.bmc.2023.117295_b0225","unstructured":"Das J., Barrish J.C., Wityak J. Preparation of benzothiazolecarboxamides as protein tyrosine kinase inhibitors. WO9924035A1, May 20, 1999."},{"key":"10.1016\/j.bmc.2023.117295_b0230","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/14756366.2019.1651723","article-title":"Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities","volume":"34","author":"Jaballah","year":"2019","journal-title":"Journal of Enzyme Inhibition and Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2023.117295_b0235","unstructured":"Yamamoto K., Kanai T., Yoshida K., Imaeda T., Esaki M. Bromodomain and extra-terminal domain (BET) degrader comprising two ligand molecules connected with linker. WO2021065980A1, April 08, 2021."},{"key":"10.1016\/j.bmc.2023.117295_b0240","unstructured":"Bi Y., Carson K.G., Cianchetta G., et al. Preparation of pyrazolo[1,5-a]pyrimidine-based compounds as adaptor associated kinase 1 inhibitors, compositions comprising them, and methods of their use. WO2013134228A1, September 12, 2013."},{"key":"10.1016\/j.bmc.2023.117295_b0245","unstructured":"Bartolome-Nebreda J.M., Macdonald G.J., Van Gool M.L.M., Conde-Ceide S., Delgado-Jimenez F. Preparation of substituted 6-(1-piperazinyl)pyridazines as 5-HT6 receptor antagonists. WO2010000456A1, January 07, 2010."},{"key":"10.1016\/j.bmc.2023.117295_b0250","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.bmc.2014.12.001","article-title":"Exploring the gyrase ATPase domain for tailoring newer anti-tubercular drugs: Hit to lead optimization of a novel class of thiazole inhibitors","volume":"23","author":"Jeankumar","year":"2015","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.bmc.2023.117295_b0255","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1248\/cpb.c14-00509","article-title":"Synthesis and in vivo evaluation of novel quinoline derivatives as phosphodiesterase 10A inhibitors","volume":"62","author":"Hamaguchi","year":"2014","journal-title":"Chemical & Pharmaceutical Bulletin"},{"key":"10.1016\/j.bmc.2023.117295_b0260","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/2213335605666180227154226","article-title":"Microwave Assisted Amination of 2-Chloro Azoles with Various Substituted Aryl Piperazines and Aryl Sulfonylpiperazines Under Neat Conditions","volume":"5","author":"Kumar","year":"2018","journal-title":"Curr. Microwave Chem."},{"key":"10.1016\/j.bmc.2023.117295_b0265","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1021\/jo401778e","article-title":"Microwave-Assisted Protection of Primary Amines as 2,5-Dimethylpyrroles and Their Orthogonal Deprotection","volume":"78","author":"Walia","year":"2013","journal-title":"The Journal of Organic Chemistry"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623001438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089623001438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:22:15Z","timestamp":1760836935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089623001438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":53,"alternative-id":["S0968089623001438"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117295","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2023.117295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117295"}}